4 recruiting, 1 completed, 1 enrolling by invitation, 1 not yet recruiting. 4 Phase 1, 2 Phase 2, 1 Not applicable, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Recruiting 2, Completed 1, Terminated 1 |
| Phase 2 | 2 | Recruiting 2 |
| Not applicable | 1 | Recruiting 1 |
| Phase 3 | 1 | Not yet recruiting 1 |
Follow Head and Neck (HNSCC): new trials by email Literature Review of Head and Neck (HNSCC) trials Research Report on Head and Neck (HNSCC)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| HYperfractionated Radiation Therapy Versus Concurrent Chemoradiation for Head and Neck Cancer (HYTC) 70 gy 35 fractions/7weeks+high dose of cisplatin, 81.6 Gy /68 fractions BID FOR 7 WEEKS - Head and Neck (HNSCC) | Not applicable | Recruiting | King Hussein Cancer Center | 604 | 2026-08-20 | 2026-10-14 |
| APG-157 in Locally Advanced Head and Neck Squamous Cell Carcinoma APG-157, Surgery, Radiation/Chemotherapy - Head and Neck Cancer, Head and Neck (HNSCC) | Phase 3 | Not yet recruiting | Aveta Biomics, Inc. | 826 | 2026-07-01 | 2026-07-01 |
| Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors CP-383 - Solid Tumor Malignancies, Colorectal Carcinoma | Phase 1 / Phase 2 | Recruiting | Tasca Therapeutics | 150 | 2025-08-27 | 2026-02-18 |
| A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Products No additional intervention administered in this long term follow-up study - Solid Tumor Cancer, Solid Tumor, Unspecified, Adult | Enrolling by invitation | A2 Biotherapeutics Inc. | 400 | 2025-07-31 | 2026-05-20 | |
| A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors GI-108 - Advanced Solid Tumor, Metastatic Solid Tumor | Phase 1 / Phase 2 | Recruiting | GI Innovation, Inc. | 102 | 2025-04-22 | 2026-09-17 |
| Matching Primary Tumor and Blood Gene Expression Analysis of HPV-negative Squamous Head and Neck Cancers Standard of Care (Investigator Choice) - Head and Neck (HNSCC) | Recruiting | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 300 | 2025-02-18 | 2026-04-06 | |
| Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications BBI-355, Erlotinib, Futibatinib - Triple Negative Breast Cancer (TNBC), High Grade Serous Ovarian Carcinoma | Phase 1 | Terminated | Boundless Bio, Inc. | 85 | 2023-03-24 | 2026-08-19 |
| Dose Finding Study Of PF-05212384 With Paclitaxel And Carboplatin In Patients With Advanced Solid Tumor PF-05212384, Paclitaxel, Carboplatin - Breast Cancer, NSCLC | Phase 1 | Completed | Cristiana Sessa | 17 | 2014-04-01 | 2019-05-21 |
Squamous Cell Carcinoma of Head and Neck (8) · Small Cell Lung Carcinoma (4) · Carcinoma, Non-Small-Cell Lung (3) · Pancreatic Neoplasms (3) · Carcinoma, Renal Cell (2) · Colorectal Neoplasms (2) · Head and Neck Neoplasms (2) · Neoplasm Metastasis (2) · Ovarian Neoplasms (2) · Triple Negative Breast Neoplasms (2) · Breast Neoplasms (1) · Endometrial Neoplasms (1) · Histiocytoma, Malignant Fibrous (1) · Kidney Neoplasms (1) · Leiomyosarcoma (1)
Carcinoma (8) · Carcinoma, Squamous Cell (8) · Neoplasms (8) · Neoplasms by Histologic Type (8) · Neoplasms by Site (8) · Neoplasms, Glandular and Epithelial (8) · Head and Neck Neoplasms (6) · Bronchial Neoplasms (5) · Carcinoma, Bronchogenic (5) · Lung Diseases (5) · Lung Neoplasms (5) · Respiratory Tract Diseases (5) · Respiratory Tract Neoplasms (5) · Thoracic Neoplasms (5) · Endocrine Gland Neoplasms (4)
Carboplatin (1) · Drug Therapy (1) · Erlotinib Hydrochloride (1) · Paclitaxel (1) · Radiation (1) · Standard of Care (1) · Surgical Procedures, Operative (1) · futibatinib (1) · gedatolisib (1)
A2 Biotherapeutics Inc. (1) · Aveta Biomics, Inc. (1) · Boundless Bio, Inc. (1) · Cristiana Sessa (1) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (1) · GI Innovation, Inc. (1) · King Hussein Cancer Center (1) · Tasca Therapeutics (1)
United States (3) · Italy (1) · Jordan (1) · South Korea (1) · Switzerland (1)
Anastasios Stathis, Prof. (1) · Eric Ng, MD (1) · Lisa Licitra (1) · Robert Doebele, MD, PhD (1)